Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARD-101 for Hyperphagia in Prader-Willi Syndrome
NCT06828861Phase 3Terminated
- Sponsor
- Aardvark Therapeutics, Inc.
- Start
- Dec 2024
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of ARD-101 in Prader-Willi syndrome (PWS) and hyperphagia (2 arms), sponsored by Aardvark Therapeutics, Inc. Primary endpoint: Hyperphagia Questionnaire for Clinical Trials Score at 12 weeks. Started Dec 2024; status: terminated.
02
Drugs
ARD-101
03
Conditions
Prader-Willi syndrome (PWS)hyperphagia
Beyond the preview
Go deeper on NCT06828861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828861.